CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 118 enrolled
Drug / intervention
Dexmedetomidine +1 moredrug
Likely dose
Dexmedetomidine 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03117790
NCT03117790Phase 4Completed

Impact of Dexmedetomidine Supplemented Analgesia on Sleep Quality in Elderly Patients After Major Surgery: A Randomized, Double-blind, and Placebo-controlled Pilot Study

Peking University First Hospital·interventional·Posted Apr 18, 2017·Updated Feb 10, 2021

In Brief

A Phase 4 clinical trial evaluating Dexmedetomidine and Placebo for Elderly and 5 related conditions. Completed, enrolled 118 participants across 1 site.

Detailed Summary

Sleep disturbances frequently occur in elderly patients after major surgery; and their occurrence are associated with worse outcomes including increased incidence of delirium. Previous studies showed that, for elderly patients admitted to the ICU after non-cardiac surgery, low-dose dexmedetomidine infusion improved to some degree the quality of sleep and reduced the incidence of delirium. The investigators hypothesize that, for elderly patients after major non-cardiac surgery, dexmedetomidine supplemented analgesia can also improve the sleep quality. The purpose of this randomized controlled pilot study is to investigate the impact of dexmedetomidine supplemented analgesia on the sleep quality in elderly patients after major non-cardiac surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedApr 18, 2017
Enrollment StartJun 26, 2017
Primary CompletionJan 16, 2020
Study CompletionFeb 18, 2020
TodayJul 1, 2026
Enrollment to primary: 2.6 yearsPosted 9.2 years ago

Interventions

Dexmedetomidinedrug

Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.

Placebodrug

Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.